BioNTech to Inaugurate First African Site on December 18, 2023
12 December 2023 - 10:45PM
BioNTech to Inaugurate First African Site on December 18, 2023
MAINZ, Germany, December 12,
2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX,
“BioNTech” or “the Company”) will inaugurate its first African site
in Kigali, Rwanda, on Monday, December 18th, 2023. The inauguration
takes place on the occasion of the set-up of the containers for the
first manufacturing unit called BioNTainer.
BioNTech invites media and the general public to
join a live stream of the event on the same day at 2:00 pm CET. The
statements of high-level dignitaries including official government
representatives as well as members of BioNTech’s board will be
broadcasted in addition to the ceremonial ribbon cutting. The live
stream will be available via this link, which will be activated on
the event day.
A replay of the stream will be available via the
“Events & Presentations” page of the Investor Relations section
of the Company’s website at www.BioNTech.com. This will be
available shortly after the conclusion of the event on the
Company’s website for seven days following the event.
About BioNTechBiopharmaceutical New
Technologies (BioNTech) is a next generation immunotherapy company
pioneering novel therapies for cancer and other serious diseases.
The Company exploits a wide array of computational discovery and
therapeutic drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product
candidates includes individualized and off-the-shelf mRNA-based
therapies, innovative chimeric antigen receptor (CAR) T cells,
several protein-based therapeutics, including bispecific immune
checkpoint modulators, targeted cancer antibodies and antibody-drug
conjugate (ADC) therapeutics, as well as small molecules. Based on
its deep expertise in mRNA vaccine development and in-house
manufacturing capabilities, BioNTech and its collaborators are
developing multiple mRNA vaccine candidates for a range of
infectious diseases alongside its diverse oncology pipeline.
BioNTech has established a broad set of relationships with multiple
global pharmaceutical collaborators, including Duality Biologics,
Fosun Pharma, Genentech, a member of the Roche Group, Genevant,
Genmab, OncoC4, Regeneron, Sanofi and Pfizer.
For more information, please visit
www.BioNTech.com.
CONTACTS
Investor RelationsVictoria Meissner,
M.D.+1 617 528 8293Investors@biontech.de
Media RelationsJasmina Alatovic+49
(0)6131 9084 1513Media@biontech.de
Biontech (LSE:0A3M)
Historical Stock Chart
From Apr 2024 to May 2024
Biontech (LSE:0A3M)
Historical Stock Chart
From May 2023 to May 2024